Please assess the completion status of the following clinical trial:

Trial Title: HIV - Monotherapy in Switzerland (MOST-ch)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* HIV seropositive.~* HAART (\> 6 months) with at least 3 months successfully suppressed HIV- RNA (two most recent RNA measurements \< 50 cp/ml). HAART is defined as either:~  * 1 PI plus 2 NRTIs,~ * 1 NNRTI plus 2 NRTIs, or~ * 3 NRTIs.~* HIV-RNA in plasma \< 50 cp/ml at screening.~* Stable antiretroviral therapy (unchanged drug combination) during the last four weeks.~* If not currently on a LPV/ r based therapy, willing to switch to LPV/ r bid therapy in case patient is randomized to the monotherapy arm~* Signed written informed consent.~* Highly motivated patients able to understand the investigational nature of this open observational study and willing to participate in additional procedures.~Exclusion Criteria:~* Other investigational substance or substances active against HIV.~* Previous history of adverse events with the drugs under investigation.~* Previous history of any virological treatment failure (does not include deliberate treatment interruption) or documented resistance against the drugs under investigation (LPV/r).~* Patient who has no effective alternative treatment options in case the study treatment fails (according to the physician's judgment).~* Pregnancy (negative pregnancy test for women of childbearing potential at screening).~* Active AIDS-defining disease necessitating antibiotic or chemotherapy at the time of screening.~* Chronic hepatitis B.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monotherapy (Type: EXPERIMENTAL): Ritonavir-boosted lopinavir (Kaletra®) will be used as monotherapy
- Continued ART (Type: ACTIVE_COMPARATOR): Continuation Therapy, conventional triple HAART

Based on this trial design, predict the completion outcome and termination type (if applicable).